|
|
|
| Analysis of the Efficacy of Singulair in Combination with Symbicort in Elderly Patients with Stable COPD |
| ZHANG Qilong, MA Yanmei, MA Honghong, et al |
| Yulin First Hospital, Shaanxi Yulin 719000, China |
|
|
|
|
Abstract Objective: To investigate the effect of Singulair combined with Symbicort on elderly patients with stable chronic obstructive pulmonary disease (COPD). Methods: Prospectively, 198 elderly patients with stable COPD admitted to our hospital between January 2019 and May 2021 were selected for the study, and all patients were divided into groups A, B and C using simple random grouping, and were given cisplatin (montelukast sodium tablets), cisplatin duplex (budesonide formoterol inhaler), cisplatin + cisplatin duplex, respectively, on the basis of conventional symptomatic management for 12 weeks. The respiratory function, inflammatory response, disease control status, clinical efficacy and incidence of adverse effects were compared before and after the intervention in the three groups. Results: In all three groups, FEV1, FVC, FEV1/FVC ratio and PaO2 were significantly higher than before the intervention, while PaCO2, sputum neutrophils, eosinophil ratio, IL-8, MPO level and total CAT questionnaire score were significantly lower than before the intervention (P<0.05). When comparing between groups, the differences in FEV1, FVC, FEV1/FVC, PaO2, PaCO2, sputum neutrophils, eosinophil ratio, IL-8, MPO level and total CAT questionnaire score before and after intervention were significantly higher in group C than in groups A and B during the same period, and the differences in FEV1/FVC, PaO2, PaCO2, sputum neutrophil ratio, IL-8, MPO level and total CAT questionnaire score before and after intervention were significantly higher in group B. The overall effective rate of group C was 95.5%, which was significantly higher than that of group A (74.2%) and group B (80.3%) (P<0.017). All patients did not suffer from serious complications such as liver and kidney function damage, cardiac arrhythmia and skeletal muscle tremor, etc. The difference in the incidence of each complication among the three groups was not statistically significant (P>0.05), and all patients recovered after symptomatic treatment without affecting the treatment process. Conclusion: Singulair combined with Symbicort could significantly improve the symptoms, respiratory function and airway inflammation of elderly patients with stable COPD, which is safe, effective and worthy of clinical application.
|
|
|
|
|
|
[1] 周小曼,林梅,张裕田.经鼻高流量氧疗治疗慢性阻塞性肺疾病合并高碳酸血症疗效及对患者血浆EOS水平和血气分析指标的影响[J].河北医学,2021,27(4):604-609.
[2] 李霞,李容华,徐林,等.高强度间歇训练对老年慢性阻塞性肺疾病合并骨质疏松患者康复效果的临床研究[J].中国医学前沿杂志(电子版),2019,11(5):30-34.
[3] 黄旺,汤枚华,叶忠桂,等.噻托溴铵联合孟鲁司特治疗早期COPD的临床观察[J].中外医学研究,2021,19(28):36-39.
[4] 张春燕,任大鹏.布地奈德福莫特罗吸入治疗对COPD合并肺癌稳定期患者的疗效及对肺功能的影响[J].湖南师范大学学报(医学版),2019,16(6):166-169.
[5] 郝文东,王国芳,张彩莲.双水平气道正压通气联合布地奈德福莫特罗对慢性阻塞性肺疾病急性加重合并Ⅱ型呼吸衰竭患者肺康复作用[J].中国老年学杂志,2019,34(3):560-562.
[6] 杨学成,陈广湛,戴武强.孟鲁司特对慢性阻塞性肺疾病合并肺间质纤维化患者肺功能及血清炎性因子的影响[J].临床医学工程,2019,26(5):601-602.
[7] 杨建明.孟鲁司特钠对慢阻肺患者抗氧化能力与胶原指标表达的影响研究[J].中国医学创新,2019,16(25):9-12.
[8] 朱美夏.布地奈德福莫特罗粉吸入剂对COPD稳定期患者肺功能及运动耐力的影响[J].基层医学论坛,2019,23(31):4583-4584. |
|
|
|
2022, Vol. 28 
